Active Drug Surveillance Program of Ferriprox Use

Status Completed

Clinical Trial Summary

Observational, open label, prospective, multi-center, post-marketing drug surveillance program.

Clinical Trial Description

A post-marketing, drug surveillance program evaluating the use, monitoring, benefits and adverse effects of Ferriprox under clinical conditions in newly treated patients. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01838291
Study type	Observational
Source	ApoPharma
Contact
Status	Completed
Phase	N/A
Start date	June 2010
Completion date	April 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00560820` - Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload	Phase 1
Completed	`NCT00390858` - A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.	Phase 2
Completed	`NCT01039636` - Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload	Phase 1
Completed	`NCT00673608` - Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload	Phase 4
Completed	`NCT00600938` - Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload	Phase 2
Withdrawn	`NCT01927913` - Treatment of Iron Overload Requiring Chelation Therapy	Phase 2
Completed	`NCT01241357` - High-Tc Susceptometer to Monitor Transfusional Iron Overload	Phase 2
Completed	`NCT01044186` - A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity	Phase 2
Completed	`NCT00379483` - Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload	Phase 2
Terminated	`NCT01326845` - Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study	Phase 4
Completed	`NCT01186419` - Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload	Phase 2
Terminated	`NCT01363908` - Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload	Phase 2